Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).

Abstract: A method of treating Middle East Respiratory syndrome (MERS) includes administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising fisetin and a pharmaceutically acceptable carrier.

Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.

Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.

Abstract: A 6-(6-bromo-2-oxo-2H-chromen-3-yl)-4-(3-bromophenyl)-2-alkoxynicotinonitrile compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A treatment method for cerebral vasospasm involves determining amounts of let-7b-5p, miR-9-3p, miR-142-3p, miR-15b-5p, miR-17-5p, miR-19b-3p, miR-20a-5p, miR-24-3p, miR-29a-3p, miR-125b-5p, and miR-142-3p in a biological sample obtained from a subject following aneurysmal subarachnoid hemorrhage (aSAH) to identify the subject as having an elevated risk of cerebral vasospasm, and administering a treatment to the subject when the elevated risk of cerebral vasospasm is identified.

Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.

Abstract: A 2-(benzo[d]oxazol-2-yl)-N?-(nicotinoyloxy)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.

Abstract: The presently-disclosed subject matter generally relates to methods for detecting the presence of amylin in a patient's erythrocytes, determining the risk for the development of prediabetes, type-2 diabetes or comorbidities thereof, and methods of treating said diseases and risks.

Abstract: A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of 8,9-unsaturated sterols in the OPCs, the agent comprising a compound having the formula (I): wherein variables Y1, R1 and R2 are as defined herein.

Abstract: Disclosed are compounds having the following structure: CDK-L-(X)n, where CDK is a CDK4/6 inhibitor group, L is a linking group, X is a radiolabel or hydrogen, n is 1, 2, 3, 4, or 5, and when there are a plurality of X groups, at least one X is a radiolabel. Also described are methods of making and using the compounds. The compounds may be used in PET imaging to quantify CDK4/6 expression in cancers and to treat cancer patients exhibiting tumors which express CDK4/6.

Abstract: Nutritional compositions contain a mixture of ketogenic ingredients including from 80 to 99% weight % 1,3-butanediol (BDO), preferably R-1,3-butanediol, and from 1 to 20 weight % beta-hydroxybutyric acid (BHB), preferably D-beta-hydroxybutyric acid, or an equivalent molar amount of its conjugate base beta-hydroxybutyrate, salts, monoesters, polyesters, or mixtures thereof. In some embodiments, the nutritional compositions for providing ketosis are prepared for oral administration in a solid form, such as bars, bites, tablets, pills or capsules, in a liquid form, such as smoothies, goos, water, carbonated beverages, soft drinks, fermented beverage suspensions, solutions and emulsions, or in a powder form that can be used to prepare drink mixes or can be added as a supplement to other food or drink products. Methods of providing ketosis in a subject include delivering optimal therapeutic ketosis, with rapidity into and extended duration of blood concentrations of D-BHB of between 1 mM and 2.5 mM.

Abstract: The invention provides compounds of formula I: and salts thereof wherein R1-R5 have any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis).

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: The present disclosure relates to osteoinductive putties and other implantable compositions for repair of bone defects and other medical uses. Specifically, the technology pertains to carriers for use in implantable compositions, such as osteoinductive putties. The osteoinductive putties are made entirely from donor tissue such as demineralized bone matrix, and the putties have excellent physical properties. The present disclosure relates to osteoinductive putties, carriers, compositions, implants, kits, methods of making and methods of using any of the foregoing.

Abstract: The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).

Abstract: Methods of inhibiting and/or reducing the occurrences and/or duration of microbial infections, such as rhinovirus and influenza infections, are provided herein. The methods comprise delivering an oral composition comprising at least one Eh-raising compound and at least one zinc compound to a subject.

Abstract: The present invention relates to a combination product and its use in therapy.

Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A (A2A) receptor antagonist or a combination of an adenosine-A2A (A2A) receptor antagonist and a programmed cell death protein 1 (PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.